Login / Signup

Overcoming limitations in current measures of drug response may enable AI-driven precision oncology.

Katja OvchinnikovaJannis BornPanagiotis ChouvardasMaria Anna RapsomanikiMarianna Kruithof de Julio
Published in: NPJ precision oncology (2024)
Machine learning (ML) models of drug sensitivity prediction are becoming increasingly popular in precision oncology. Here, we identify a fundamental limitation in standard measures of drug sensitivity that hinders the development of personalized prediction models - they focus on absolute effects but do not capture relative differences between cancer subtypes. Our work suggests that using z-scored drug response measures mitigates these limitations and leads to meaningful predictions, opening the door for sophisticated ML precision oncology models.
Keyphrases
  • machine learning
  • palliative care
  • artificial intelligence
  • adverse drug
  • squamous cell carcinoma
  • big data
  • young adults
  • deep learning